MOTS-c is scientifically distinctive - a peptide encoded inside mitochondrial DNA that acts like a metabolic signal - and it earned a spot in the FDA's July 2026 compounding review, which sent search interest vertical. The science is early but real; the marketing runs years ahead of it.
What MOTS-c is
MOTS-c ('mitochondrial open reading frame of the twelve S rRNA type-c') is a 16-amino-acid peptide encoded within mitochondrial DNA. In published research it translocates to the nucleus under metabolic stress and regulates genes tied to glucose handling and cellular energy - behaving like an exercise-responsive hormone. Levels decline with age, feeding the longevity narrative.
The evidence base
- Animal data: improved insulin sensitivity, exercise capacity, and resistance to diet-induced obesity in mice - the studies behind the 'exercise in a vial' framing.
- Human data: observational studies linking MOTS-c levels to metabolic health, plus very small early-phase work. No adequately powered human efficacy trial for any indication as of August 2026.
- Regulatory: reviewed by the FDA's Pharmacy Compounding Advisory Committee in July 2026 alongside BPC-157 and others. Committee recommendations are consultative - no reclassification has been enacted, and no legal compounding pathway exists today.
The dosage math
Gray-market MOTS-c is denominated in milligrams (typical vials 5-10 mg). A 10 mg vial with 2 ml of bacteriostatic water is 5 mg/ml; a 5 mg amount would be a full 1 ml - 100 units, the entire capacity of the largest insulin syringe, which is exactly the kind of practical constraint the calculator flags before you're holding a syringe wondering why it doesn't fit.
Safety unknowns
Short human exposures in early studies did not surface acute safety signals, but there is no long-term human dataset for exogenous MOTS-c by any route. As a metabolic signaling peptide, the theoretical questions (insulin signaling interactions, chronic AMPK activation) are unstudied in humans. Research-vial purity adds the usual layer of practical risk.
Frequently asked questions
Did the FDA ban or approve MOTS-c in 2026?
Neither. The July 2026 PCAC meeting reviewed it for potential compounding eligibility; recommendations are consultative and no status change has been enacted. It remains an unapproved compound with no legal compounding pathway as of August 2026.
What is MOTS-c used for?
In research: metabolic regulation, insulin sensitivity, and exercise-capacity models, almost entirely in animals. Marketed uses (fat loss, endurance, longevity) have not been demonstrated in controlled human trials.
What's a typical MOTS-c dosage?
No human dose is evidence-established. Gray-market discussion clusters around 5-10 mg once or twice weekly - extrapolation, not data. The calculator converts whatever amount a clinician specifies into syringe units.